3D-Conformal Hypofractionated Radiotherapy for Prostate Cancer with Daily Transabdominal Ultrasonography Prostate Localization: Toxicity and Outcome of a Pilot Study
Restricted accessResearch articleFirst published online November, 2010
3D-Conformal Hypofractionated Radiotherapy for Prostate Cancer with Daily Transabdominal Ultrasonography Prostate Localization: Toxicity and Outcome of a Pilot Study
To evaluate the feasibility, toxicity and patient outcome of hypofractionated 3-dimensional conformal radiotherapy for low- and intermediate-risk prostate cancer, using daily an ultrasound targeting system (BAT™).
Methods
Between May 2005 and October 2006, 25 patients (cT1-T2, GS ≤7, mean initial PSA = 7.06 ng/ml) received a dose of 72 Gy in 30 fractions. Only the prostate was included in the clinical target volume. Immediately before each radiotherapy session, BATTM ultrasound alignment was performed. Acute and late toxicity was evaluated according to the Radiation Therapy Oncology Group criteria; the Phoenix definition (PSA = nadir + 2 ng/ml) was applied to define biochemical failure. BATTM localization data were provided for 300 out of 750 procedures.
Results
No interruptions in 3-dimensional conformal radiotherapy due to toxicity were registered. There was no acute rectal toxicity in 52% of patients; 28% had G1, 16% had G2, and 1 patient had a G3 event. No acute urinary toxicity was observed in 28% of the patients. G1 toxicity occurred in 40%, G2 in 28%, and G3 in 1 patient; no G4 event was observed. With an average follow-up of 45 months, one biochemical relapse was observed; late toxicity showed an excellent profile: 78% of the patients had no rectal toxicity, 16% had G1, and 1 patient had G2 toxicity. Most of the patients (68%) had no late urinary complications, whereas 32% had G1 toxicity. Localization data showed systematic and random errors in relation to some procedure biases.
Conclusions
Promising tumor control and toxicity profile were observed with this mildly hypofractionated BAT-based 3-dimensional conformal radiotherapy. Free full text available at www.tumorionline.it
HanksG.E., MartzK.L., DiamondJ.J.: The effect of dose on local control of prostate cancer. Int J Radiat Oncol Biol Phys, 15: 1299–1305, 1988.
2.
MichalskiJ.M., PurdyJ.A., WinterK., RoachM.3rd, VijayakumarS., SandlerH.M., MarkoeA.M., RitterM.A., RussellK.J., SailerS., HarmsW.B., PerezC.A., WilderR.B., HamnksG.E., CoxJ.D.: Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys, 46: 391–402, 2000.
3.
MichalskiJ.M., WinterK., PurdyJ.A.: Update of toxicity following 3D radiation therapy for prostate cancer on RTOG 9406. Int J Radiat Oncol Biol Phys, 48(suppl): 233, 2000.
4.
PollackA., HanlonA.L., HorwitzE.M., FeigenbergS.J., KonskiA.A., MovsasB., GreenbergR.E., UzzoR.G., MaC.M., mcNeeleyS.W., BuyyounouskiM.K., Price RAJ.r.: Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionated dose escalation trial. Int J Radiat Oncol Biol Phys, 64: 518–526, 2006.
5.
van Tol-GeerdinkJ.J., StalmeierP.F., Pasker-De JongP.C.M., HuizengaH., van LinE.N., SchimmelE.C., LeerJ.W., van DaalW.A.: Systematic review of the effect of radiation dose on tumor control and morbidity in the treatment of prostate cancer by 3D-CRT. Int J Radiat Oncol Biol Phys, 64: 534–543, 2006.
6.
ZelefskyM.J., LeibelS.A., GaudinP.B., KutcherG.J., FleshnerN.E., VenkatramenE.S., ReuterV.E., FairW.R., LingC.C., FucksZ.: Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys, 41: 491–500, 1998.
7.
ZietmanA.L., DeSilvioM.L., SlaterJ.D., RossiC.J.Jr., MillerD.W., AdamsJ.A., ShipleyW.U.: Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA, 294: 1233–1239, 2005.
8.
HanlonA.L., SchultheissT.E., HuntMA., MovsasB., PeterR.S., HanksG.E.: Chronic rectal bleeding after high dose conformal treatment of prostate cancer warrants modification of existing morbidity scales. Int J Radiat Oncol Biol Phys, 38: 59–63, 1997.
9.
ICRU Report 62.Prescribing, recording and reporting photon beam therapy (supplement to ICRU report 50).Bethesda: International Commission on Radiation Units and Measurements, 1999.
10.
PollackA., ZagarsG.K., StarkschallG., AntolakJ.A., LeeJ.J., HuangE., von EschenbachA.C., KubanD.A., RosenI.: Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys, 53: 1097–1105, 2002.
11.
Jereczek-FossaB.A., CattaniF., GaribaldiC., ZeriniD., CambriaR., BobocG.I., ValentiM., KowalczykA., VavassoriA., IvaldiG.B., CioccaM., MateiD.V., De CobelliO., OrecchiaR.: Trans-abdominal ultrasonography, computed tomography and electronic portal imaging for 3-dimensional conformal radiotherapy for prostate cancer. Strahlenther Onkol, 183: 610–616, 2007.
12.
LattanziJ., McNeeleyS., PinoverW., HorwitzE., DasI., SchultheissT.E., HanksG.E.: A comparison of daily CT localization to a daily ultrasound-based system in prostate cancer. Int J Radiat Oncol Biol Phys, 43: 719–725, 1999.
KupelianP.A., ThakkarV.V., KhuntiaD., ReddyC.A., KleinE.A., MahadevanA.: Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: long term results. Int J Radiat Oncol Biol Phys, 63: 1463–1468, 2005.
15.
LukkaH., HayterC., JulianJ.A., WardeP., MorrisW.J., GospodarowiczM., LevineM., SathyaJ., ChooR., PrichardH., BrundageM., KwanW.: Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. JCO, 23: 6132–6138, 2005.
16.
LukkaH., HayterC., WardeP., MorrisJ., JulianJ., GospodarowiczM., LevineM., Investigators’ of OCOG Prostate Fractionartion/NCIC CTG PRS Study: A randomized trial comparing two fractionated schedules for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys, 57(suppl): S126, 2003.
17.
MohanD.S., KupelianP.A., WilloughbyT.R.: Short-course intensity-modulated radiotherapy for localized prostate cancer with daily transabdominal ultrasound localization of the prostate gland. Int J Radiat Oncol Biol Phys, 46: 575–580, 2000.
18.
LivseyJ.E., CowanR.A., WylieJ.P., SwindellR., ReadG., KhooV.S., LogueJ.P.: Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis. Int J Radiat Oncol Biol Phys, 57: 1254–1259, 2003.
19.
AkimotoT., MuramatsuH., TakahashiM., SaitoJ., KitamotoY., HarashimaK., MiyazawaY., YamadaM., ItoK., KurokawaK., YamanakaH., NakanoT., MitsuhashiN., NiibeH.: Rectal bleeding after hypofractionated radiotherapy for prostate cancer: correlation between clinical and dosimetric parameters and the incidence of grade 2 or worse rectal bleeding. Int J Radiat Oncol Biol Phys, 60: 1033–1039, 2004.
20.
KitamuraK., ShiratoH., ShinoharaN., HarabayashiT., OnimaruR., FujitaK., ShimizuS., NonomuraK., KoyanagiT., MiyasakaK.: Reduction in acute morbidity using hypofractionated intensity-modulated radiation therapy assisted with fluoroscopic real-time tumour-tracking system for prostate cancer: Preliminary result of a phase I/II study. Cancer J, 9: 268–276, 2003.
21.
WangJ.Z., GuerreroM., LiX.A.: How low is the α/β ratio for prostate cancer?Int J Radiat Oncol Biol Phys, 55: 194–203, 2003.
22.
BrennerD.J., MartinezA.A., EdmundsonG.K., MitchellC., ThamesH.D., ArmourE.P.: Direct evidence that prostate tumours show high sensitivity to fractionation (low α/β ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys, 52: 6–13, 2002.
23.
DubrayB.M., ThamesH.D.: Chronic radiation damage in the rat rectum: an analysis of the influences of fractionation, time and volume. Radiother Oncol, 33: 41–47, 1994.
24.
FowlerJ.F., RitterM.A., ChappellR.J., BrennerD.J.: What hypofractionated protocols should be tested for prostate cancer?Int J Radiat Oncol Biol Phys, 56: 1093–1104, 2003.
25.
GuckenbergerM., PohlF., BaierK., MeyerJ., KoelblO., FlentjeM., VordermarkD.: Influence of rectum delineation (rectal volume vs. rectal wall) on IMRT treatment planning of the prostate. Strahlenther Onkol, 182: 721–726, 2006.
26.
BoehmerD., KuczerD., BadakhshiH., StiefelS., KuschkeW, WerneckeK.D., BudachV.: Influence of organ at risk definition on rectal dose-volume histograms in patients with prostate cancer undergoing external-beam radiotherapy. Strahlenther Onkol, 182: 277–282, 2006.
27.
GrecoC., MazzettaC., CattaniF., TosiG., CastiglioniS., FodorA., OrecchiaO.: Finding dose-volume constraints to reduce late rectal toxicity following 3D-conformal radiotherapy (3D-CRT) of prostate cancer. Radiother Oncol, 69: 215–222, 2003.
28.
RoachM.III, HanksG., ThamesH.Jr, SchellhammerP., ShipleyW.V., SokolG.H., SandeuH.: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference. Int J Radiat Oncol Biol Phys, 65: 965–974, 2006.
29.
YeohE.E., HollowayR.H., FraserR.J., BottenR.J., DiMatteoA.C., ButtersJ., WeerasingheS., AbeysingheP.: Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys, 66: 1072–1083, 2006.
30.
BouchetL.G., MeeksS.L., GoodchildG., BovaF.J., BuattiJ.M., FriedmanW.A.: Calibration of three-dimensional ultrasound images for image-guided radiation therapy. Phys Med Biol, 46: 559–577, 2001.
31.
TomeW.A., MeeksS.L., OrtonN.P., BouchetL.G., BovaF.J.: Commissioning and quality assurance of an optically guided three-dimensional ultrasound target localization system for radiotherapy. Med Phys, 29: 1781–1788, 2002.
32.
McGahanJ., RyuJ., FogataM.: Ultrasound probe pressure as a source of error in prostate localization for external beam radiotherapy, Int J Radiat Oncol Biol Phys, 60: 788–793, 2004.
33.
ArtignanX., SmitsmansM.H., LebesqueJ.V., JaffrayD.A., van HerkM., BartelinkH.: Online ultrasound image guidance for radiotherapy of prostate cancer: impact of image acquisition on prostate displacement. Int J Radiat Oncol Biol Phys, 59: 595–601, 2004.
